MEP3208A - Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama - Google Patents

Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama

Info

Publication number
MEP3208A
MEP3208A MEP-32/08A MEP3208A MEP3208A ME P3208 A MEP3208 A ME P3208A ME P3208 A MEP3208 A ME P3208A ME P3208 A MEP3208 A ME P3208A
Authority
ME
Montenegro
Prior art keywords
modified
polypeptides
pharmacokinetic properties
chimeric polypeptides
modified chimeric
Prior art date
Application number
MEP-32/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Nicholas J Papadopoulos
Samuel Davis
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP3208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MEP3208A publication Critical patent/MEP3208A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
MEP-32/08A 1999-06-08 2000-05-23 Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama MEP3208A (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08
PCT/US2000/014142 WO2000075319A1 (en) 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties

Publications (1)

Publication Number Publication Date
MEP3208A true MEP3208A (xx) 2010-02-10

Family

ID=22480568

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2008-32A ME00024B (me) 1999-06-08 2000-05-23 Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
MEP-32/08A MEP3208A (xx) 1999-06-08 2000-05-23 Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2008-32A ME00024B (me) 1999-06-08 2000-05-23 Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama

Country Status (33)

Country Link
EP (2) EP1183353B1 (xx)
JP (2) JP4723140B2 (xx)
KR (1) KR100659477B1 (xx)
CN (3) CN100523187C (xx)
AT (2) ATE293164T1 (xx)
AU (2) AU779303B2 (xx)
BE (1) BE2013C029I2 (xx)
BR (2) BRPI0011407B8 (xx)
CA (1) CA2376379C (xx)
CY (2) CY1108883T1 (xx)
CZ (2) CZ302689B6 (xx)
DE (2) DE60041159D1 (xx)
DK (2) DK1183353T3 (xx)
ES (2) ES2319305T3 (xx)
FR (1) FR13C0028I2 (xx)
HK (3) HK1043388A1 (xx)
HR (1) HRP20010908B1 (xx)
HU (3) HU229156B1 (xx)
IL (3) IL146890A0 (xx)
LT (1) LTC1183353I2 (xx)
LU (1) LU92195I2 (xx)
ME (2) ME00024B (xx)
MX (1) MXPA01012630A (xx)
NO (3) NO330775B1 (xx)
NZ (1) NZ515913A (xx)
PL (1) PL208247B1 (xx)
PT (2) PT1544299E (xx)
RS (1) RS50073B (xx)
RU (1) RU2265661C2 (xx)
SK (1) SK287332B6 (xx)
UA (1) UA74146C2 (xx)
WO (1) WO2000075319A1 (xx)
ZA (1) ZA200110068B (xx)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
ATE359300T1 (de) 2001-01-19 2007-05-15 Ludwig Inst Cancer Res Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
EP1575548B1 (en) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
CA2519787C (en) * 2003-03-28 2012-06-05 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking vegf-mediated activity
ES2616749T3 (es) 2003-05-16 2017-06-14 Acorda Therapeutics, Inc. Mutantes degradantes del proteoglucano para el tratamiento del SNC
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP1646353A4 (en) * 2003-05-16 2008-06-04 Acorda Therapeutics Inc FUSION PROTEINS FOR THE TREATMENT OF THE CENTRAL NERVOUS SYSTEM
AU2004242586C1 (en) * 2003-05-28 2011-02-24 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using VEGF antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
EP1631317A2 (en) * 2003-06-06 2006-03-08 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005016369A1 (en) * 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
WO2005112986A2 (en) 2004-05-18 2005-12-01 Acorda Therapeutics, Inc. Purifying chondroitinase and stable formulations thereof
EP1767546B1 (en) * 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
US7354580B2 (en) * 2004-06-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
US20050281822A1 (en) * 2004-06-18 2005-12-22 Cedarbaum Jesse M Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion
AU2005267741A1 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
ATE470454T1 (de) 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
LT2586459T (lt) 2005-03-25 2017-09-25 Regeneron Pharmaceuticals, Inc. Vegf antagonisto kompozicijos
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
WO2007070671A2 (en) † 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
ES2406764T3 (es) 2006-06-16 2013-06-10 Regeneron Pharmaceuticals, Inc. Formulaciones que comprenden antagonistas de VEGF para administración intravítrea
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
JP5391069B2 (ja) 2006-10-10 2014-01-15 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を使用する組成物及び方法
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
CA2742241C (en) 2008-11-03 2019-12-10 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
JP5965318B2 (ja) 2009-10-16 2016-08-03 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストおよび降圧剤の治療的併用およびそれらによる治療の方法
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
LT2601214T (lt) 2010-08-06 2018-02-26 Genzyme Corporation Vegf antagonistų kompozicijos ir jų panaudojimas
JP6043629B2 (ja) * 2011-01-07 2016-12-14 中外製薬株式会社 抗体の物性を改善させる方法
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
EP2785744B1 (en) * 2011-12-01 2017-10-04 AP Biosciences, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
ES2753135T3 (es) 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
SI2956476T1 (sl) 2013-02-18 2020-03-31 Vegenics Pty Limited Molekule za vezavo na ligande in uporabe le-teh
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
US20150126458A1 (en) 2013-11-05 2015-05-07 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
CN106456757A (zh) 2014-05-12 2017-02-22 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
CN106999511A (zh) 2014-12-11 2017-08-01 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
WO2017087871A1 (en) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2017087798A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
MX2018006171A (es) 2015-11-18 2018-12-19 Formycon Ag Jeringa de plastico precargada que contiene un antagonista de vegf.
CN108697792A (zh) * 2015-11-19 2018-10-23 珠海泰瑞尚生物医药科技有限公司 用于结合vegf的方法和组合物
CA3007276C (en) 2015-12-03 2021-12-28 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitor to treat macular degeneration in a patient population
WO2017129685A1 (en) 2016-01-26 2017-08-03 Formycon Ag Liquid formulation of a vegf antagonist
WO2018070390A1 (ja) 2016-10-12 2018-04-19 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
EP3668985B1 (en) 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
CA3081094A1 (en) 2017-11-20 2019-05-23 Alison J. GILLESPIE Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
SG11202004545XA (en) * 2017-11-27 2020-06-29 4D Molecular Therapeutics Inc Adeno-associated virus variant capsids and use for inhibiting angiogenesis
DK3716992T3 (da) 2017-11-30 2022-09-12 Regeneron Pharma Anvendelse af en VEGF-antagonist til behandling af angiogene øjenlidelser
MX2020005699A (es) 2017-12-13 2020-10-16 Regeneron Pharma Dispositivos y sistemas para manipulacion de soportes de lecho de columna para cromatografia y metodos relacionados.
EP3743091A4 (en) * 2018-01-26 2021-12-15 The Regents of the University of California METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANGIOGENIC DISORDERS USING ANTI-VEGF AGENTS
EP3790532A1 (en) 2018-05-10 2021-03-17 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
WO2020229584A1 (en) 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
US20210060258A1 (en) 2019-09-03 2021-03-04 Amgen Inc. Injection device for drug delivery and packaging for the injection device
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
AU2020397053A1 (en) 2019-12-06 2022-06-23 Regeneron Pharmaceuticals, Inc. VEGF mini-traps and methods of use thereof
SG11202110968VA (en) * 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
MX2022010177A (es) 2020-02-24 2022-09-12 Amgen Inc Envases y sistemas para su uso durante la esterilizacion externa de dispositivos de administracion de farmacos.
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
WO2024029876A1 (ko) * 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
HU229156B1 (en) 2013-09-30
EP1183353A1 (en) 2002-03-06
HK1132653A1 (en) 2010-03-05
ATE417928T1 (de) 2009-01-15
JP2003501089A (ja) 2003-01-14
KR100659477B1 (ko) 2006-12-20
NO20016036L (no) 2002-02-08
CN101433715A (zh) 2009-05-20
ES2237429T3 (es) 2005-08-01
CY2013019I2 (el) 2015-11-04
BR0011407A (pt) 2002-04-02
RS50073B (sr) 2009-01-22
CN100523187C (zh) 2009-08-05
EP1544299B1 (en) 2008-12-17
IL146890A (en) 2008-07-08
HRP20010908A2 (en) 2005-04-30
AU2005201365A1 (en) 2005-04-28
CA2376379C (en) 2007-08-07
DK1544299T3 (da) 2009-03-23
ATE293164T1 (de) 2005-04-15
WO2000075319A1 (en) 2000-12-14
PT1544299E (pt) 2009-03-18
NO20100656L (no) 2002-02-08
PL208247B1 (pl) 2011-04-29
NO20016036D0 (no) 2001-12-10
NZ515913A (en) 2004-01-30
DE60019415D1 (de) 2005-05-19
FR13C0028I1 (fr) 2013-06-14
AU779303B2 (en) 2005-01-13
ES2319305T3 (es) 2009-05-06
MXPA01012630A (es) 2002-07-22
CN101433715B (zh) 2013-04-17
RU2265661C2 (ru) 2005-12-10
DE60041159D1 (de) 2009-01-29
NO2013010I2 (no) 2013-05-15
HUS1300052I1 (hu) 2016-08-29
CY1108883T1 (el) 2014-07-02
HRP20010908B1 (en) 2006-05-31
NO2013010I1 (no) 2013-06-17
CZ20014387A3 (cs) 2002-10-16
IL146890A0 (en) 2002-08-14
HU230159B1 (hu) 2015-09-28
FR13C0028I2 (fr) 2014-05-16
KR20020019070A (ko) 2002-03-09
SK17522001A3 (sk) 2003-04-01
ME00024B (me) 2010-02-10
JP4723140B2 (ja) 2011-07-13
BRPI0011407B1 (pt) 2018-09-25
SK287332B6 (sk) 2010-07-07
DE60019415T2 (de) 2006-03-09
JP2011024595A (ja) 2011-02-10
EP1544299A1 (en) 2005-06-22
CY2013019I1 (el) 2015-11-04
YU86901A (sh) 2004-05-12
PL352246A1 (en) 2003-08-11
HK1043388A1 (en) 2002-09-13
CA2376379A1 (en) 2000-12-14
IL190234A0 (en) 2008-11-03
ZA200110068B (en) 2002-12-06
BRPI0011407B8 (pt) 2021-05-25
AU2005201365B2 (en) 2007-08-09
HK1185798A1 (en) 2014-02-28
AU5040400A (en) 2000-12-28
DK1183353T3 (da) 2005-08-08
CN103349781B (zh) 2015-04-01
PT1183353E (pt) 2005-06-30
UA74146C2 (uk) 2005-11-15
LU92195I2 (fr) 2013-07-15
BE2013C029I2 (xx) 2019-03-06
JP5273746B2 (ja) 2013-08-28
CN103349781A (zh) 2013-10-16
HUP0201515A3 (en) 2004-12-28
NO332559B1 (no) 2012-10-29
CN1369009A (zh) 2002-09-11
LTC1183353I2 (lt) 2023-02-27
LTPA2013009I1 (lt) 2013-06-25
NO330775B1 (no) 2011-07-11
EP1183353B1 (en) 2005-04-13
CZ303656B6 (cs) 2013-01-30
CZ302689B6 (cs) 2011-09-07
HUP0201515A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
MEP3208A (xx) Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
MXPA03006806A (es) Metodo para usar variante del receptor del factor de crecimiento celular endotelial vascular para tratar psoriasis y para mejorar curacion de heridas.
IL144654A0 (en) Pancreatic progenitor cells, methods and uses related thereto
MXPA02000012A (es) Polipeptidos hibridos con propiedades farmacocineticas mejoradas.
AU2001291687A1 (en) Polyammonium-polysiloxane compounds, methods for the production and use thereof
PL349841A1 (en) Triazole compounds with dopamine-d3-receptor affinity
IL146482A (en) Tek antagonists
MY120601A (en) C-21 modified epothilones
NO20001408L (no) Smal MWD, optimalisert etylen interpolymerblanding, fremgangsmÕte for fremstilling derav og gjenstander fremstilt derav
ZA200201494B (en) Benzodiazepin derivatives, the production and use thereof.
WO2001000244A3 (en) METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
BG108494A (en) Pulmonary administration of chemically modified insulin
TWI317736B (en) Methods for the production of redox proteins and heteromultimeric-protein-complexes, and related compositions related applications
ZA200007771B (en) Textile spun-dyed fiber material and use thereof for producing camouflage articles.
IL145018A0 (en) Perfluoroalkylamide, the production thereof and the use thereof in diagnostics
AU7937600A (en) Wholly elastic knitted fabrics and methods of producing the same
AU2580300A (en) Cloth for sportswear, use of said cloth in producing sportswear, and also said sportswear
DK1065277T3 (da) Alfa-amylasemutanter
AU2011501A (en) Benzimidazoles, production thereof and the use thereof as antithrombotic
WO2002058635A3 (en) Nicotine immunogens and antibodies and uses thereof
CU23070A3 (es) Reduccion de la capa fludizada de finos de laterita con reduccion de gases generados in situ.
ZA200103695B (en) Process for the manufacture in pure form of 1-pentene or alpha-olefin lower than 1-pentene.
MXPA02002859A (es) Formulaciones para uso parenteral del fosfato de estramustina con propiedades farmacologicas mejoradas.
YU8999A (sh) Vertikalni nosači za mini roletne
AU4930100A (en) Stitching machine for the tip of knitted tubular articles such as stockings and the like, in particular retention articles